Journal of Family Medicine and Primary Care (Jan 2022)

Diffuse large B-cell lymphoma and new insights into its pathobiology and implication in treatment

  • Garima Mamgain,
  • Praveen K Singh,
  • Priyanka Patra,
  • Manisha Naithani,
  • Uttam K Nath

DOI
https://doi.org/10.4103/jfmpc.jfmpc_2432_21
Journal volume & issue
Vol. 11, no. 8
pp. 4151 – 4158

Abstract

Read online

The most common non-Hodgkin lymphoma (NHL) subtype is diffuse large B-cell lymphoma (DLBCL). It accounts for roughly 30% of all cases of NHL affecting both nodal and extra nodal sites. There are molecular subtypes of DLBCL, germinal centre subtype (GCB), and activated B-cell (ABC), based on gene expression profiling (GEP), in accumulation to distinct morphological and clinicopathological subtypes. To prognosticate patients, the International Prognostication Index (IPI) and its variants are used. In ABC type DLBCL, limited stage disease is treated with a combination of abbreviated systemic chemotherapy (three cycles) and field radiation therapy. Although advanced stage disease is treated with a full course of chemotherapy as well as novel agents (Bortezomib, Ibrutinib, Lenalidomide). In this review study, we looked at the role of multiple aspects of genetic and microenvironment changes which have effects in DLBCL tumours.

Keywords